Cosmo announces regulatory approval of GI Genius(TM) in Canada Mittwoch, 17. November 2021 - 07:01
|
Cosmo Pharmaceuticals N.V. / Key word(s): Regulatory Approval Cosmo announces regulatory approval of GI Genius(TM) in Canada Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Ad hoc announcement pursuant to Art. 53 LR Dublin, Ireland - November 17, 2021: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) ('Cosmo') today announced that GI Genius(TM) has received regulatory approval in Canada. GI Genius(TM) is an AI-enhanced endoscopy aid device for the detection of colorectal lesions during colonoscopy. The GI Genius(TM) intelligent endoscopy module offers a transformative solution, powered by Artificial Intelligence, to address the challenges of detecting colorectal cancer early. GI Genius(TM) was developed by Cosmo and is marketed worldwide by Medtronic, the global leader in medical technology. GI Genius(TM) is already approved in the US, EU, Israel, UAE and Australia. GI Genius(TM) works in real-time as an aid to the gastroenterologist during a colonoscopy for the purpose of highlighting regions with visual characteristics consistent with different types of mucosal abnormalities, such as colorectal polyps of all shapes, sizes, and morphology. It is designed to be integrated with all existing gastrointestinal endoscopes. Alessandro Della Chà, CEO of Cosmo, commented: 'It is very good to see GI Genius(TM) rapidly becoming a real global franchise'. About Cosmo Pharmaceuticals Contact End of ad hoc announcement |
